Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Fox Chase Cancer Center · City Of Hope National Medical Center · +42 more institutions
Abstract
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN…
Citation impact
- FWCI
- 50.77
- Percentile
- 100%
- References
- 138
Authors
34Topics & keywords
- Medicine
- Soft tissue sarcoma
- Sarcoma
- Rhabdomyosarcoma
- Soft tissue
- Clinical Practice
- Surgical oncology
- Head and neck
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- APAmylin Pharmaceuticals
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- KTKaryopharm Therapeutics
- RPRegeneron Pharmaceuticals
- EExelixis
- APAstex Pharmaceuticals
- COClovis Oncology
- DPDeciphera Pharmaceuticals
- IIncyte
- ITIterion Therapeutics
- STSpringworks Therapeutics
- BHBayer HealthCare
- DDaiichi-Sankyo
- EEisai
- SServier
- PPlexxikon
- ESEMD Serono
- LOLoxo Oncology
- FMFoundation Medicine
- NCNational Cancer Institute